Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis
KA Papp, A Blauvelt, M Bukhalo… - … England Journal of …, 2017 - Mass Medical Soc
Background Interleukin-23 is thought to be critical to the pathogenesis of psoriasis. We
compared risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits
interleukin-23 by specifically targeting the p19 subunit and thus prevents interleukin-23
signaling, and ustekinumab, an interleukin-12 and interleukin-23 inhibitor, in patients with
moderate-to-severe plaque psoriasis. Methods We randomly assigned a total of 166 patients
to receive subcutaneous injections of risankizumab (a single 18-mg dose at week 0 or 90 …
compared risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits
interleukin-23 by specifically targeting the p19 subunit and thus prevents interleukin-23
signaling, and ustekinumab, an interleukin-12 and interleukin-23 inhibitor, in patients with
moderate-to-severe plaque psoriasis. Methods We randomly assigned a total of 166 patients
to receive subcutaneous injections of risankizumab (a single 18-mg dose at week 0 or 90 …
Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
M Fioranelli, MG Roccia, T Lotti - Dermatologic Therapy, 2017 - search.ebscohost.com
The article offers information on a study conducted to find the effect of risankizumab and
ustekinumab in patients with moderate-to-severe plaque psoriasis. It discusses evaluation of
drugs in terms of reduction from baseline in the psoriasis area and severity index. it also
discusses selective blockade of interleukin-23 with risankizumab.
ustekinumab in patients with moderate-to-severe plaque psoriasis. It discusses evaluation of
drugs in terms of reduction from baseline in the psoriasis area and severity index. it also
discusses selective blockade of interleukin-23 with risankizumab.
以上显示的是最相近的搜索结果。 查看全部搜索结果